One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF Agents

Figures & data

Figure 1 Definition of the brolucizumab, BRO and ALT cohorts.

Abbreviations: ALT, brolucizumab alternating with another anti-VEGF; BRO, brolucizumab only; VEGF, vascular endothelial growth factor.

Table 1 Clinical and Baseline Characteristics of Patients and Eyes in the BRO and ALT Cohorts

	12 Months Follow Up			18 Months Follow Up
	BRO Cohort N=174 Eyes from 154 Patients	ALT Cohort N=47 Eyes from 41 Patients	p-value (per Eye)	BRO Cohort N=95 Eyes from 85 Patients	ALT Cohort N=29 Eyes from 24 Patients
Age, years, mean (SD)	80.7 (7.9)	77.7 (8.9)	0.0241	79.9 (7.5)	80.0 (7.2)
Gender*
Female: n, %	98 (56.3%)	28 (59.6%)	0.7191	53 (55.8%)	18 (62.1%)
VA (ETDRS letters; mean [SD])	60.8 (17.1)	61.4 (16.0)	0.8377	64.7 (15.9)	64.7 (14.6)
Pre-switch injection interval, mean days (SD)	47.8 (25.1)	32.0 (10.5)	<0.0001	45.7 (23.9)	32.7 (10.3)
Follow up period, mean days (SD)	562.8 (104.8)	570.0 (113.5)	0.6829	642.4 (47.8)	649.3 (53.6)
CMT, µm (mean [SD])	292.2 (113.3)^†	288.0 (89.6)	0.8169	283.7 (76.2)^‡	266.1 (64.5)
IRF, n (%)	40 (23.0%)	15 (31.9%)	0.2091	19 (20.0%)	6 (20.7%)
SRF, n (%)	102 (58.6%)	24 (51.1%)	0.3531	55 (57.9%)	14 (48.3%)
PED, n (%)	109 (62.6%)	26 (55.3%)	0.5501	55 (57.9%)	16 (55.2%)

Notes: *Gender not known for 1 patient belonging to the 12-month BRO cohort and the 18-month BRO cohort; ^†n=162 eyes; ^‡n=91 eyes.

Abbreviations: ALT, brolucizumab alternating with another anti-VEGF cohort; BRO, brolucizumab only cohort; CMT, central macular thickness; ETDRS, Early Treatment Diabetic Retinopathy Study; IRF, intraretinal fluid; PED, pigment epithelial detachment; SD, standard deviation; SRF, subretinal fluid; VA, visual acuity.

Table 2 Visual Acuity Change from Baseline at Months 12 and 18

	12-Month BRO Cohort (N=174 Eyes)*	p-value	12-Month ALT cohort (N=47 eyes)	p-value
VA change from baseline at Month 12 (mean [95% CI] ETDRS letters	−1.1 (−3.4, 1.2)	0.34	1.3 (−2.6, 5.2)	0.51
ETDRS letter vision change from baseline at Month 12 (n [%])
≥30 letters gained	3 (1.7)	–	2 (4.3)	–
≥15 to <30 letters gained	13 (7.5)	–	1 (2.1)	–
≥5 to <15 letters gained	26 (14.9)	–	5 (10.6)	–
<5 letters lost to <5 letters gained	94 (54.0)	–	28 (59.6)	–
≥5 to <15 letters lost	19 (10.9)	–	7 (14.9)	–
≥15 to <30 letters lost	7 (4.0)	–	2 (4.3)	–
≥30 letters lost	10 (5.7)	–	0 (0.0)	–
	18-month BRO cohort (N=95 eyes)	P-value	18-month ALT cohort (N=29 eyes)	P-value
VA change from baseline at Month 18 (mean [95% CI] ETDRS letters	0.0 (−2.8, 2.7)	0.98	−7.3 (−13.9, −0. 8)	0.03
ETDRS letter vision change from baseline at Month 12 (n [%])
≥30 letters gained	2 (2.1)	–	0 (0.0)	–
≥15 to <30 letters gained	8 (8.4)	–	1 (3.4)	–
≥5 to <15 letters gained	12 (12.6)	–	1 (3.4)	–
<5 letters lost to <5 letters gained	47 (49.5)	–	18 (62.1)	–
≥5 to <15 letters lost	20 (21.1)	–	4 (13.8)	–
≥15 to <30 letters lost	3 (3.2)	–	2 (6.9)	–
≥30 letters lost	3 (3.2)	–	3 (10.3)	–

Note: *Two eyes in the 12-month and 18-month BRO cohorts had light perception only and were excluded from the VA analysis.

Abbreviations: ALT, brolucizumab alternating with another anti-VEGF cohort; BRO, brolucizumab only cohort; CI, confidence interval; ETDRS, Early Treatment Diabetic Retinopathy Study; ETDRS, Early Treatment Diabetic Retinopathy Study; VA, visual acuity.

Figure 2 Anti-VEGF agents and injection intervals for eyes in the 12-month (A) BRO cohort (n=174 eyes) and (B) ALT cohort (n=47 eyes).

Abbreviations: ALT, brolucizumab alternating with another anti-VEGF; BRO, brolucizumab only; VEGF, vascular endothelial growth factor.

Figure 3 Mean change in (A) injection intervals and (B) CMT from baseline to Month 12 in the BRO and ALT cohorts.

Abbreviations: ALT, brolucizumab alternating with another anti-VEGF; BRO, brolucizumab only; CI, confidence interval; CMT, central macular thickness; N, number of eyes; VA, visual acuity.